Clinical Trial

PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-26.
Trial Details
NCT Number NCT06617481
Lead Sponsor AdventHealth
Collaborators: Blue Earth Diagnostics
Conditions Prostate Cancer (Post Prostatectomy)
Enrollment 30 participants
Start Date 2024-09-20
Primary Completion 2027-09-05 (estimated)
Study Completion 2027-10-10 (estimated)
Updated on ClinicalTrials.gov 2024-10-24